AIM

SEC Filing Summary: Hemispherx Biopharma, Inc. (10-Q)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2006 for Hemispherx Biopharma, Inc., a biopharmaceutical company focused on immune system-enhancing technologies. The company's primary products are Ampligen(R) (under clinical development for ME/CFS, HIV, and influenza) and Alferon N Injection(R) (FDA-approved for genital warts). The filing includes restated financial data for the prior year period due to accounting errors regarding convertible debentures and stock-based compensation.

Key Financial Metrics

Liquidity: As of June 27, 2006, the company held approximately $22 million in cash and short-term investments, sufficient for operations and debt service for the next 18 months.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss nearly doubled to $5.92 million, driven primarily by a $1.95 million increase in stock-based compensation expense due to the adoption of FAS 123R, a $1.16 million increase in R&D costs, and higher production costs.
• Revenue Decline: Total revenue decreased 8.5% to $236,000. Sales of Alferon N Injection(R) dropped 20% due to competition, while clinical treatment program revenue for Ampligen(R) increased 83%.
• Debt Reduction: Long-term debt decreased by approximately $647,000 due to investor conversions of debentures into common stock ($3.65 million principal converted year-to-date) and installment payments.
• Equity Financing: The company raised $10.6 million net from a private placement and warrant exercises during the quarter, significantly boosting cash reserves.

Outlook, Risks, and Contingencies

• Regulatory Status: The company is preparing a New Drug Application (NDA) for Ampligen(R) for ME/CFS. A pre-NDA meeting with the FDA is scheduled for August 2, 2006. The FDA has requested a complete audited report of the AMP 516 study to evaluate "fast track" designation.
• Financing Agreements: On April 12, 2006, the company entered a new agreement with Fusion Capital to sell up to $50 million of common stock over 25 months. A previous $20 million agreement was completed in April 2006.
• Legal and Compliance Risks:
  • Delisting Threat: The company failed to timely file its 2005 10-K and Q1 2006 10-Q, violating AMEX listing rules and debenture covenants. A waiver was obtained from debenture holders, and the AMEX granted an extension until June 30, 2006. The filings were subsequently submitted in June 2006.
  • Liquidated Damages: Due to filing delays, the company is subject to liquidated damages of approximately $2,748 per day until shares are registered for resale, estimated not to exceed $425,000.
  • Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding the recording of convertible debentures and stock-based compensation, necessitating the restatement of prior periods.
• Product Risks: No assurance exists that Ampligen(R) will receive FDA approval or that Alferon N Injection(R) will gain approval for new indications. Manufacturing capacity for commercial scale remains a challenge.

Investor Verification Checklist

• Restatement Impact: Verify the full extent of the restatements for 2003-2005 and the specific accounting errors regarding EITF 00-27 and FAS 123.
• Debt Covenants: Confirm the status of the waiver regarding the late filing and the calculation of accrued liquidated damages.
• Fusion Capital Agreement: Review the terms of the new $50 million purchase agreement, specifically the 9.9% beneficial ownership limit and the requirement for stockholder approval to exceed 19.99% of outstanding shares.
• NDA Timeline: Monitor the outcome of the August 2, 2006, pre-NDA meeting with the FDA regarding Ampligen(R).
• Manufacturing Capacity: Assess the progress of the new raw material production line in New Jersey and the contract manufacturing agreement with Hollister-Stier.